European Group for Research in Schizophrenia Stichting

Schizophrenia Research

The sponsor’s clinical research is centered on schizophrenia, with particular attention to symptoms that affect daily functioning and long-term outcomes.

  • Cognitive impairment
  • Cognitive function
  • Adult schizophrenia

Its funded trial activity focuses on understanding treatment effects in adults living with schizophrenia, especially in relation to thinking, memory, and other cognitive domains.

Psychiatric Disorders

Clinical interest extends to the broader area of psychiatric disorders, with emphasis on symptoms that interfere with social and occupational functioning.

  • Neuropsychiatry
  • Functional impairment
  • Symptom management

The sponsor’s research activity is aligned with therapeutic questions relevant to persistent mental health burden in schizophrenia.

Neurocognitive Health

A key therapeutic domain is neurocognitive health, reflecting interest in how treatment may support attention, memory, and overall cognitive performance.

  • Attention
  • Memory
  • Executive function

This area highlights the sponsor’s focus on outcomes that are closely tied to independence and everyday functioning in people with schizophrenia.

Adult Mental Health

The sponsor is involved in research concerning adult mental health, particularly in populations living with chronic psychotic illness.

  • Adults with schizophrenia
  • Chronic psychiatric illness
  • Daily functioning

Its trial portfolio indicates interest in therapeutic strategies aimed at improving clinically meaningful outcomes for adults affected by schizophrenia.

Want to learn more about this study or check if you can participate? Contact us.

Matched clinical trials

  • A study to evaluate the effect of xanomeline tartrate and trospium chloride on cognitive impairment in adults with schizophrenia.

    Not yet recruiting

    1 1 1
    Austria Belgium Czechia Denmark Germany Hungary +3